Ann Oncol 2001, 12:1127–1131.PubMedCrossRef 26. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ: Nuclear expression of the c-erbB-4/HER-4 growth factor receptor
in invasive breast cancers. Cancer Res 2000, 60:1483–1487.PubMed 27. Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR: Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid PRIMA-1MET cost carcinomas. Cancer Res 1996, 56:1184–1188.PubMed 28. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41:1127–1132.PubMedCentralPubMedCrossRef 29. Kurppa K, Elenius K: Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res 2009, 22:708–710.PubMedCrossRef selleck screening library 30. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, Kim VN, Kim KS: Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004, 270:488–498.PubMedCrossRef 31. Bourguignon LY, Wong
G, Earle C, Chen L: Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression click here leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012, 287:32800–32824.PubMedCrossRef 32. Murray MJ, Erastin clinical trial Saini HK, van Dongen S, Palmer RD, Muralidhar B, Pett MR, Piipari M, Thornton CM, Nicholson JC, Enright AJ, Coleman N: The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression. Mol Cancer 2010, 9:290.PubMedCentralPubMedCrossRef 33. Wang L, Yao J, Shi X, Hu L, Li Z, Song T, Huang C: MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer 2013, 13:448.PubMedCentralPubMedCrossRef 34. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA: Regulatory mechanisms of microRNAs
involvement in cancer. Expert Opin Biol Ther 2007, 7:1009–1019.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions MZ, LZ and QY constructed the manuscript. MZ, LZ and QY were responsible for clinical data and evaluated clinical data; formed analysis of relation between clinical data and survival data. QY, SZ and WY carried out intro experiments. ZL, CH, QW, and JW reviewed the manuscript. All authors read and approval the final manuscript.”
“Background c-Jun NH2-terminal kinases (JNKs) are strongly activated by a variety of stressful cellular environments, such as chemotherapy and oxidative stress, and induce growth inhibition or cell death [1, 2].